RDM is defined as technology, systems and strategies that change the economics and organisation of manufacturing, particularly in relation to location and scale. Smaller-scale precision manufacturing can radically reduce supply chain costs, improve sustainability and tailor products to the needs of patients and consumers.
The Redistributed Manufacturing in Healthcare Network (RiHN) – aiming to help position the UK at the forefront of Healthcare Manufacturing
The RiHN aims to deliver a single vision of the research needed to position the UK at the forefront of healthcare manufacturing.
Following a successful £0.5m award from the Engineering and Physical Services Research Council (EPSRC), the RiHN is being led by a multi-disciplinary team that spans the disciplines of manufacturing, healthcare technologies, management and human factors. Network Director Dr Wendy Phillips is leading the two-year project commencing from February 2015.
What is Redistributed Manufacturing?
There are a number of drivers underpinning the exploration and adoption of redistributed manufacturing in healthcare. Find out how RiHN researchers and associates are seeking to advance the RDM in healthcare research.
Join our Network
We invite clinicians, SMEs, large enterprise, academia and other institutions interested in advancing the Redistributed Manufacturing (RDM) in healthcare agenda to support our feasibility studies and assist us with our research. We aim to deliver guidance on pathways for RDM innovations in healthcare, as well as expert recommendations for future research and investment in this area.
Our Research Team
The RiHN Research team includes members from the University of Cambridge, Loughborough, Nottingham, Newcastle, the West of England and Brunel University. Join our network for the opportunity to discuss the challenges of Redistributed Manufacturing in Healthcare with experts in the field.
The adoption of redistributed manufacturing (RDM) in the healthcare sector is driven by a number of factors. These include the risk of committed capital, the impact on the complexity of existing supply chains, capacity management, sustainability requirements, and the adoption of new technologies. The RiHN has commissioned several feasibility studies to advance the understanding of the challenges and opportunities of RDM. The below videos give an overview of each project.
The way we currently manufacture our goods is becoming increasingly unsustainable. The centralised, off-shore approach has come under threat by global economic volatility, security risks, and climate change. Watch the video and find out what solutions Redistributed Manufacturing can offer to commonly faced challenges.
Video: Cell Microfactories: Feasibility Study in the Redistributed Manufacture of Cell-Based Therapeutics
Video: 3-D Bioprinting of Islet Micro-tissues to Redistribute Manufacture for Treatment of Type 1 Diabetes
Richard P Harrison, Qasim A Rafiq & Nicholas Medcalf on why decentralised, or redistributed manufacture, is likely to be the manufacturing approach of choice for some cell- and gene-based therapies, in particular, personalised therapies.